3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
D000368:Aged; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D004185:Disability Evaluation; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008750:Methyldopa / Q000008:administration & dosage / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000188:drug therapy*; D013997:Time Factors; D014282:Trihexyphenidyl / Q000008:administration & dosage / Q000627:therapeutic use*
D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D014282:Trihexyphenidyl